-
Sector Analysis
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Small-Cell Lung Cancer (SCLC) Therapeutics. - In 2025, there were 232,630 diagnosed prevalent cases of SCLC in the 16 countries covered in GlobalData’s epidemiology forecast. - Over the past decades, the SCLC treatment landscape was dominated by Etoposide and Platinum (EP), with few and only modestly effective relapse treatments and minimal therapeutic differentiation. Currently, adding PD‑L1 inhibitors to chemotherapy is the standard first-line approach in Extensive...
-
Sector Analysis
Hodgkin Lymphoma: Epidemiology Report and Forecast
Hodgkin lymphoma (HL) is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. The exact cause of HL is unclear; however, 20–40% of HL cases had a prior diagnosis of infectious mononucleosis caused by the Epstein-Barr virus (EBV). HL originates...
-
Sector Analysis
Glioblastoma (GBM): Epidemiology Report and Forecast, 2026
Glioblastoma multiforme (GBM) is a highly aggressive form of glioma, a cancer arising from astrocytes, and is the most common type of brain tumor in adults (Kanderi et al., 2024). The distinction of “multiforme” comes from the wide range of genetic expressions characteristic of the cancer, complicating treatment (Kanderi et al., 2024). Glioblastoma multiforme is currently incurable, with a median survival time of 15 months and a 7.2% five-year survival rate (Kanderi et al., 2024). Gold standard treatment is a...
-
Product Insights
Multiple Myeloma (Kahler Disease) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) - Global Clinical Trials Review, 2026" provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Oral Cavity (Mouth) Cancer: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Oral Cavity (Mouth) Cancer - Global Clinical Trials Review, 2026" provides an overview of Oral Cavity (Mouth) Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oral Cavity (Mouth) Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Esophageal Cancer: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Esophageal Cancer - Global Clinical Trials Review, 2026" provides an overview of Esophageal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Esophageal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Hepatocellular Carcinoma: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hepatocellular Carcinoma - Global Clinical Trials Review, 2026" provides an overview of Hepatocellular Carcinoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Mycosis Fungoides: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Mycosis Fungoides - Global Clinical Trials Review, 2026" provides an overview of Mycosis Fungoides Clinical trials scenario. This report provides top line data relating to the clinical trials on Mycosis Fungoides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Melanoma: Epidemiology Forecast to 2035
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, which is the most superficial layer of the skin (World Health Organization, 2017). Melanoma typically presents as a mole (nevus) on the skin, and is characterized by the growth’s asymmetry, irregular border, color variation, diameter greater than six millimeters, and evolution in appearance over a few weeks or months (Gadeliya Goodson and Grossman, 2009; Goodman and Snyder, 2012). This report focuses on melanoma...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.